Synthetic Peptide
ASAH1 Synthetic Peptide, PEP-0694, from Invitrogen.
ASAH1 encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. The processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene have been linked to the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. The related pathways include Innate Immune System and Sphingolipid metabolism. Diseases associated with ASAH1 include Farber Lipogranulomatosis and Spinal Muscular Atrophy With Progressive Myoclonic Epilepsy.
| Marque | Invitrogen |
|---|---|
| Réf. B-LABO | BL-RE-177017 |
| Réf. fabricant | 15378900 |
| Gene ID (Entrez) | 427 |
| Espèces | Human |
| Méthode de purification | purified |
| Numéro d’adhésion | Q13510 |
| Nom usuel | Human ASAH1 |
| Concentration | 200 μg/mL |
| Contenu et stockage | -20°C |
| Format | Liquid |
| Formule | PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2 |
| À utiliser avec (application) | Blocking Assay, Control |
| Symbole de gène(s) | ASAH1 |
| Lyophilisé | No |
| Conservateur | 0.02% sodium azide |
| Type de produit | Peptide |
| Quantité | 50 μg |
| État réglementaire | RUO - research use only |
| Tampon de stockage | PBS |
